Obagi Medical Products, Inc. (OMPI) Tops Q3 EPS by 7c, Sales Fall Inline
Tweet
Share
E-mailGet Alerts OMPI Hot Sheet
Join SI Premium – FREE
Obagi Medical Products, Inc. (NASDAQ: OMPI) reported Q3 EPS of $0.24, $0.07 better than the analyst estimate of $0.17. Revenue for the quarter came in at $28.1 million versus the consensus estimate of $28.16 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
- Southland Holdings (SLND) Misses Q2 EPS by 122c
- Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
